Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16353932 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL12125320 | 0.89 | SMN1; SMN2 (0.80) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL16353805 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL1696118 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL30608941 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL8869291 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL18381340 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL9369229 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL9351419 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDALOX15TDP1POLB | |
| SCHEMBL5862791 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2HPGDALOX15TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2019-05-21 | — | — | US | disclosed |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-9670242-B2 | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| EP-2824108-B1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | TIANJIN HEMAY BIO-TECH CO LTD (CN) | 2017-04-19 | — | — | EP | disclosed |
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2824108-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2015-01-14 | — | — | EP | disclosed |
| CN-104125962-A | Tetracyclic anthraquinone derivatives | TIANJIN HEMAY BIO TECH CO LTD | 2014-10-29 | — | — | CN | disclosed |
| EP-0620818-A1 | ARYL KETONES AS TESTOSTERONE 5$g(a)-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993013099-A1 | ARYL KETONES AS TESTOSTERONE 5α-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166595-A1 | Tetracyclic Anthraquinone Derivatives | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SMN1; SMN2 4065/4885HPGD 351/4885ALOX15 1943/4885 |
| US-10294260-B2 | Tetracyclic anthraquinone derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, ANTXR2 | SMN1; SMN2 2232/4885HPGD 297/4885ALOX15 1048/4885 |
| US-20170247403-A1 | TETRACYCLIC ANTHRAQUINONE DERIVATIVES | ANTXR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBXA2R | SMN1; SMN2 4065/4885HPGD 351/4885ALOX15 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.